Castle Biosciences, Inc.
CSTL
Positions held
Your positionsCSTL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Castle Biosciences operates in the growing diagnostics and research sector, focusing on innovative solutions for skin cancer management, which positions it well against competitors.
- Revenue increased by 24% compared to the prior quarter, reaching $104 million.
- Gross margin improved to 77.1%, up from 75.5% in the previous quarter.
- The company has a high debt-to-equity ratio of 7.797, indicating potential financial risk.
- In 2023, Castle Biosciences reported a net income loss of $57.466 million.
- The operating margin remains negative at -3% despite recent improvements.
Fundamentals
| Market cap | $1.03B | Enterprise value | $799.67M | Trailing P/E | — | Forward P/E | -35.90 |
| PEG | — | Price / book | 2.19 | Beta | 0.95 | Dividend yield | 0.00% |
| Revenue growth | 20.1% | Earnings growth | — | Gross margin | 77.3% | Operating margin | -3.0% |
| Profit margin | -5.4% | ROE | -4.2% | ROA | -1.4% | Debt / equity | 0.08 |
| Current ratio | 6.04 | Free cash flow | -$7.26M | Analyst recommendation | strong_buy | Mean target | $45.22 |
| 52w high | $44.28 | 52w low | $17.72 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $104M | $83.7M | $87.0M | $83.0M | $86.2M |
| Op margin | -3.0% | -22.0% | -4.4% | -8.2% | -4.9% |
| Net income | -$2.1M | -$14.5M | -$2.3M | -$0.5M | $4.5M |
| Gross margin | 77.1% | 75.5% | 79.0% | 77.5% | 79.5% |
| Gross profit | $79.8M | $63.1M | $68.7M | $64.3M | $68.6M |
| Operating income | -$3.1M | -$18.4M | -$3.8M | -$6.8M | -$4.3M |
- Revenue +24% vs prior quarter ($104M vs $84M).
- Gross margin 77.1% (was 75.5% prior quarter).
- Operating margin expanded to -3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $344M | $332M | $220M | $137M | — |
| Op margin | -12.4% | 2.6% | -30.9% | -66.5% | — |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | — |
| Gross margin | 79.4% | 81.9% | 79.5% | 76.6% | — |
| Gross profit | $273M | $272M | $175M | $105M | — |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$91.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)
2026-09-22 · Castle Biosciences to Open New Laboratory Facility in Scottsdale
2026-09-09 · JAAD Publication Shows Improved Performance of DecisionDx®-SCC
2026-08-28 · Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
2026-08-27 · Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?
2026-08-20 · Castle Biosciences to Participate in Upcoming Investor Conferences
2026-08-17 · Castle Biosciences Approved for Dual Listing on Nasdaq Texas
2026-08-13 · Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Price (daily)
Full chart · RSI · MACD · patterns